Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib, Abemaciclib, and Trastuzumab in HER2+ Metastatic Breast Cancer
NCT03846583Phase 1Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of tucatinib in breast cancer (4 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 2 years. Planned start Jun 2020; status: withdrawn.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03846583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03846583.